Ignite Creation Date:
2025-12-24 @ 9:08 PM
Ignite Modification Date:
2025-12-28 @ 8:50 PM
Study NCT ID:
NCT06909604
Status:
RECRUITING
Last Update Posted:
2025-04-03
First Post:
2024-12-24
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Al18F-HER2-BCH PET in Breast Patients Treated With Neoadjuvant Therapy
Sponsor:
Peking University Cancer Hospital & Institute
Organization:
Study Overview
Official Title:
Al18F-HER2-BCH PET/CT to Predict Response in Breast Patients Treated With Neoadjuvant Therapy
Status:
RECRUITING
Status Verified Date:
2025-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HERfore
Brief Summary:
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with neoadjuvant therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: